Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PRF1 | P14222 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242535 | 1.00 | GRM5 (0.56) | GRM5MEN1KMT2ASRD5A1AOC3 | |
| SCHEMBL30609592 | 0.86 | DRD2 (0.53) | GRM5MEN1KMT2ADRD2 | |
| SCHEMBL4126390 | 0.84 | SRD5A1 (0.43) | GRM5MEN1KMT2ASRD5A1AOC3 | |
| SCHEMBL4126388 | 0.84 | SRD5A1 (0.43) | GRM5MEN1KMT2ASRD5A1AOC3 | |
| SCHEMBL17519979 | 0.82 | UGCG (0.48) | SRD5A1PRF1 | |
| SCHEMBL18053937 | 0.81 | GRM5 (0.57) | GRM5MEN1KMT2AAOC3PRF1 | |
| SCHEMBL28941260 | 0.81 | HRH3 (0.46) | SRD5A1HRH3DRD2DRD4DRD3 | |
| SCHEMBL424393 | 0.81 | GRM5 (0.57) | GRM5MEN1KMT2ASRD5A1AOC3 | |
| SCHEMBL19699194 | 0.79 | GRM5 (0.56) | GRM5MEN1KMT2ASRD5A1AOC3 | |
| SCHEMBL172065 | 0.79 | GRM5 (0.56) | GRM5MEN1KMT2ASRD5A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291235-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | GRM5 362/4885MEN1 794/4885KMT2A 664/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | GRM5 2916/4885MEN1 2440/4885KMT2A 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.